SCHEMBL3547224

SCHEMBL3547224

CCCNC(=O)CN1CCNC(C)(C)C1=O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.38
MAPK1 P28482 1/20 0.38
POLB P06746 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
THRB P10828 1/20 0.37
LMNA P02545 2/20 0.36
MCL1 Q07820 1/20 0.36
CACNA1B Q00975 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HTT P42858 1/20 0.34
TSHR P16473 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542513 0.85 OPRM1 (0.40) MAPK1L3MBTL1LMNACACNA1BALDH1A1
SCHEMBL3541852 0.82 ACE (0.39) CACNA1B
SCHEMBL3553015 0.82 POLB (0.40) POLBCACNA1B
SCHEMBL3541459 0.78 CACNA1B (0.36) CACNA1BALDH1A1KDM4ETSHR
SCHEMBL3553474 0.77 KMT2A (0.47) POLBLMNACACNA1BCYP2C9CYP2C19
SCHEMBL3551597 0.76 CACNA1B (0.36) HSD17B10L3MBTL1LMNACACNA1BCYP2C9
SCHEMBL3548171 0.75 TSHR (0.43) POLBTHRBCACNA1BKDM4ETSHR
SCHEMBL3545537 0.75 L3MBTL1 (0.41) POLBL3MBTL1ALDH1A1KDM4E
SCHEMBL20088428 0.73 NAMPT (0.44) POLBALDH1A1KDM4ETSHR
SCHEMBL3547090 0.73 CACNA1H (0.36) CACNA1BSIGMAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741479-B2 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. (US) 2010-06-22 US disclosed
EP-1828169-A2 UREA INHIBITORS OF MAP KINASES Locus Pharmaceuticals, Inc. (US) 2007-09-05 EP disclosed
US-20060167247-A1 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. 2006-07-27 US disclosed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167247-A1 Urea inhibitors of MAP kinases MAPK1, MAP3K1, MAP3K20 HSD17B10 4110/4885MAPK1 1/4885POLB 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.